A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date8/13/192/21/23

Funding

  • Exelixis Inc.: $108,294.00